Cartilage regeneration means restoring a functional, load-bearing tissue surface rather than merely reducing joint pain. Mesenchymal stromal cell (MSC) therapy is being studied because MSCs can modify inflammation, support resident chondrocytes, and coordinate repair signals, but current human evidence does not show reliable regrowth of normal cartilage in every patient [1].

The biological challenge is unusually difficult. Articular cartilage has no blood vessels, few cells, and little access to circulating repair cells. Once a defect extends through the smooth surface, spontaneous healing is limited and the altered mechanics can accelerate degeneration.

The practical question is not simply whether stem cells “work.” It is whether a specific cell product, delivery method, joint environment, rehabilitation plan, and disease stage can produce durable tissue that behaves like cartilage. This review separates symptomatic improvement from structural regeneration and explains where MSC treatment in Bangkok may fit within an evidence-based joint-preservation plan.

What is articular cartilage regeneration?

Articular cartilage regeneration is the restoration of organized cartilage that covers a joint, distributes load, and allows low-friction movement. Healthy hyaline cartilage is built from chondrocytes embedded in a dense extracellular matrix rich in type II collagen, aggrecan, and water. That architecture is different from scar-like fibrocartilage, which can fill a defect but usually has weaker mechanical durability [2].

A focal cartilage defect and osteoarthritis are related but not identical. A focal lesion is a defined area of damage, often after trauma or sport; osteoarthritis is a whole-joint process involving cartilage, synovium, subchondral bone, meniscus, ligaments, and mechanics. A treatment that helps a small contained lesion may not restore a diffusely worn, malaligned, bone-on-bone joint.

For patients, this distinction changes expectations. Pain relief may occur through reduced synovitis even when MRI shows little new tissue. Conversely, repair tissue visible on imaging does not automatically mean normal biomechanics or permanent protection from osteoarthritis. Good studies therefore measure symptoms, function, imaging, and—when surgery allows—arthroscopic or histological tissue quality.

Why does damaged cartilage heal so poorly?

Damaged cartilage heals poorly because it is avascular, has a sparse cell population, and contains a matrix that restricts cell migration. Superficial defects do not reach marrow blood supply, so they receive little fibrin clot formation or recruitment of reparative cells. Deep osteochondral defects can access marrow progenitors, but the tissue that forms is often fibrocartilage rather than durable hyaline cartilage [3].

Age and inflammation further suppress repair. Chondrocytes exposed to IL-1β, TNF-α, oxidative stress, and abnormal loading increase catabolic enzymes such as MMP-13 and ADAMTS-5. Senescent cells produce a secretory profile that reinforces inflammation and matrix loss. The result is a repair environment that actively works against regeneration.

Mechanical alignment matters as much as biology. Varus or valgus malalignment, instability, meniscal deficiency, obesity, and repetitive overload continue to concentrate force on the injured surface. Injecting cells without correcting an adverse mechanical environment is like repairing pavement while heavy traffic continues across the wet material.

How could MSC therapy support cartilage repair?

MSC therapy may support cartilage repair mainly through signaling, immune regulation, and trophic support—not by simply turning every injected cell into a chondrocyte. Laboratory differentiation is possible, but after clinical delivery many cells remain transient. Their secretome can still influence macrophages, synovial cells, chondrocytes, endothelial cells, and endogenous progenitors [4].

These mechanisms overlap, and their importance varies by treatment. A simple intra-articular injection is primarily a joint-environment intervention. Surgical implantation in a scaffold places cells inside a defined defect and is designed more directly for tissue formation.

MSC cartilage regeneration microenvironment with chondrocytes and rebuilding extracellular matrix

Injection, scaffold, or surgery: which approach targets regeneration?

Intra-articular injection targets the biological environment of the joint, while scaffold-based or surgical approaches target a defined cartilage defect. These strategies should not be treated as interchangeable. The correct route depends on whether the main problem is diffuse osteoarthritis, a focal chondral lesion, an osteochondral defect, or a mechanical abnormality.

ApproachPrimary aimTypical settingMain limitation
Intra-articular MSC injectionReduce inflammation and support cartilage homeostasisMild-to-moderate osteoarthritisCells are not fixed inside one defect
MSC plus hyaluronic-acid hydrogelRetain cells and provide a three-dimensional matrixContained cartilage defectsProduct and technique remain specialized
MSC implantation with microfractureAugment marrow stimulation and defect fillingFocal full-thickness lesionsRequires arthroscopy and rehabilitation
Osteochondral graft or chondrocyte implantationReplace or rebuild a structural surfaceLarger focal defectsSurgical morbidity, cost, and eligibility

Microfracture creates channels into subchondral bone so marrow cells enter the defect, but long-term results can deteriorate as fibrocartilage matures. Trials combining cultured MSCs with microfracture or cartilage-derived matrices aim to improve tissue organization; some report better MOCART imaging scores, but clinical superiority is not universal [5].

What do human trials show about cartilage regrowth?

Human trials show a clearer signal for pain and function than for consistent structural cartilage regrowth. Randomized studies of intra-articular MSCs often report improvements in WOMAC, KOOS, and pain scores, yet MRI findings range from no significant change to reduced defect size, improved cartilage quality, or slower volume loss [6].

A proof-of-concept adipose-derived MSC study reported dose-related clinical improvement and arthroscopic evidence of cartilage changes, but it was small and not sufficient to establish routine regeneration [7]. A randomized placebo-controlled phase IIb trial found symptom improvement but no significant MRI cartilage-volume change at six months, illustrating why symptom and structure must be reported separately [8].

One notable scaffold-based program combined allogeneic umbilical-cord-blood MSCs with hyaluronate hydrogel for cartilage defects. Extended follow-up supported safety and durable clinical improvement, with repair tissue assessed arthroscopically and histologically in early participants [9]. This is encouraging, but it represents a specialized implanted product for selected defects—not evidence that any IV or joint injection can rebuild cartilage.

Systematic reviews reach a cautious consensus: short-term patient-reported outcomes are often favorable, while heterogeneity in cell source, expansion, dose, co-interventions, imaging, and disease severity prevents a confident universal claim of regeneration [10].

The distinction that protects patients

Less pain is not proof of new cartilage. A responsible clinic should say whether its goal is inflammation control, joint preservation, focal-defect repair, or structural regeneration—and should use an outcome measure capable of testing that goal.

Who may be a candidate for MSC cartilage treatment in Bangkok?

The most plausible candidates have a clearly characterized cartilage problem, correctable mechanics, and enough remaining joint structure to preserve. Assessment should combine history, examination, weight-bearing radiographs, and MRI when the result will change the plan. Age alone is not decisive, but biological quality, activity, alignment, and lesion size influence the probability of benefit.

Poor candidates may include people with active infection, untreated malignancy, uncontrolled coagulation problems, severe uncorrected malalignment, advanced bone-on-bone disease, or expectations of guaranteed regrowth. End-stage arthritis may be served more predictably by arthroplasty than by a biologic procedure.

How is a cartilage-regeneration plan built in Thailand?

An evidence-based cartilage plan begins with diagnosis and biomechanics, not with a preselected vial of cells. The clinician first identifies whether pain comes from cartilage, meniscus, tendon, synovium, subchondral bone, referred pain, or several structures. Imaging is interpreted alongside symptoms because many cartilage lesions are incidental.

  1. Define the lesion: location, surface area, depth, containment, subchondral bone status, and osteoarthritis grade.
  2. Map mechanical drivers: alignment, ligament stability, meniscal function, gait, body weight, and sport or work loading.
  3. Choose the therapeutic objective: symptom control, preservation, focal repair, or surgical restoration.
  4. Specify the product: tissue source, culture method, identity markers, sterility, potency rationale, dose, and fresh-delivery chain.
  5. Plan rehabilitation: protected loading when appropriate, range of motion, progressive strength, and return-to-activity criteria.
  6. Measure outcomes: baseline and follow-up KOOS/WOMAC, pain, function, and MRI only when structural assessment is justified.

For an injection, the procedure is usually performed under sterile conditions with ultrasound or fluoroscopic guidance when anatomy requires it. For an implanted scaffold, arthroscopy, defect preparation, and a longer protected-weight-bearing protocol may be necessary. A credible recommendation explains why the chosen route matches the lesion.

MSC cartilage tissue engineering scaffold placed within a focal articular cartilage defect

What quality controls matter for an MSC product?

Cell identity, sterility, viability, traceability, and manufacturing consistency matter more than a marketing label such as “stem cell.” Products described by the same broad name can differ substantially. The International Society for Cell & Gene Therapy minimum criteria help define cultured MSC identity, but they do not by themselves prove clinical potency for cartilage [11].

Fresh, never-frozen delivery avoids a freeze-thaw step, but freshness alone does not establish efficacy. It must sit within a controlled manufacturing and clinical process. Similarly, very high cell counts are not automatically better; dose-response relationships can be nonlinear and remain incompletely standardized.

What are the risks and realistic recovery expectations?

The most common short-term risks of intra-articular MSC procedures are temporary pain, swelling, stiffness, or an inflammatory flare. Infection, bleeding, and injury to nearby structures are uncommon but important procedural risks. Surgical implantation adds anesthesia, thrombosis, wound, and rehabilitation risks.

Published knee studies have generally reported reassuring short- to medium-term safety, including long-term observational follow-up after autologous bone-marrow MSC transplantation [12]. However, safety evidence for one manufactured product cannot be transferred automatically to an uncharacterized product, and long-term surveillance remains important.

Days 1–7Temporary soreness or swelling may occur; activity is modified.
Weeks 2–6Progressive mobility and strength work; symptom change may begin.
Months 2–6Functional outcomes are reassessed; biological remodeling is gradual.
Months 6–12Selected cases may undergo repeat MRI when structural change will affect care.

These are planning ranges, not promises. Recovery after an injection differs from recovery after microfracture or scaffold implantation. Rehabilitation adherence and correction of joint loading may influence durability as much as the cell intervention itself.

How should cartilage regeneration be measured?

Cartilage regeneration should be measured with separate clinical and structural endpoints because neither can substitute for the other. Patient-reported outcome measures such as KOOS and WOMAC capture pain, stiffness, sport, and daily function. Objective testing can include range of motion, strength, walking capacity, and return to activity.

Structural assessment may use MRI defect fill, cartilage thickness or volume, T2/T1rho compositional mapping, and the MOCART score after repair surgery. Arthroscopy can inspect surface integration, while biopsy can distinguish hyaline-like cartilage from fibrocartilage—but invasive assessment is rarely justified solely for research follow-up.

A before-and-after MRI image selected from different slices or sequences can be misleading. Meaningful comparison requires standardized acquisition, timing, blinded interpretation where possible, and awareness that hydration changes may alter cartilage signal without proving durable tissue formation.

What does the evidence not yet establish?

The evidence does not yet establish that MSC therapy routinely regenerates normal hyaline cartilage, reverses end-stage osteoarthritis, or prevents future joint replacement. Cell source and dose are not standardized, studies are often small, and many combine cells with surgery, hyaluronic acid, platelet products, or rehabilitation, making the active component difficult to isolate.

These limitations do not make the field irrelevant. They define the questions a responsible program must answer and protect patients from confusing plausible biology with guaranteed clinical regeneration.

Frequently Asked Questions

Can stem cells regrow knee cartilage?

Stem cells may support repair and some specialized implanted MSC products have produced cartilage-like tissue in selected focal defects. Routine injections have stronger evidence for pain and function than for consistent regrowth of normal hyaline cartilage.

Is cartilage regeneration treatment available in Bangkok?

Regenerative and orthopaedic clinics in Bangkok offer biologic joint procedures, but products, indications, and quality systems vary. Patients should seek imaging-based assessment, explicit cell-quality documentation, and conservative claims before proceeding.

Is an MSC injection the same as cartilage implantation?

No. An injection distributes cells in the joint and mainly targets inflammation and tissue support; implantation places cells or a cell-scaffold construct into a prepared focal defect, usually during surgery.

How long does cartilage regeneration take?

Biological remodeling is measured in months, not days. Symptom change can occur earlier than structural change, while scaffold or microfracture procedures often require months of protected loading and rehabilitation.

Does PRP regenerate cartilage as well as MSC therapy?

PRP provides concentrated platelet signals and can improve symptoms, but convincing evidence of durable hyaline cartilage regeneration is limited for both PRP and injectable MSC therapy. Their mechanisms, manufacturing, cost, and evidence should be compared for the specific diagnosis.

What is the best age for cartilage stem cell therapy?

There is no single age cutoff. Lesion type, remaining cartilage, alignment, metabolic health, activity goals, and ability to rehabilitate are usually more informative than chronological age alone.

Limitations and medical disclaimer

MSC-based cartilage regeneration remains investigational and should not be presented as guaranteed tissue regrowth. This review synthesizes published research across osteoarthritis and focal cartilage repair, but protocols are heterogeneous and results from one product cannot be assumed for another. Evidence is concentrated in the knee and cannot automatically be applied to the hip, ankle, shoulder, or spine.

This article is educational, not a diagnosis or treatment recommendation. A qualified clinician should review symptoms, examination findings, imaging, medical history, alternatives, costs, and uncertainties before any procedure. Standard care—including exercise therapy, weight management, medication, bracing, corrective surgery, or arthroplasty—may be more appropriate depending on disease stage.

References

  1. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nature Reviews Rheumatology. 2013;9:584–594. doi:10.1038/nrrheum.2013.109 ↩
  2. Hunziker EB. Articular cartilage repair: basic science and clinical progress. Osteoarthritis and Cartilage. 2002;10(6):432–463. doi:10.1053/joca.2002.0801 ↩
  3. Makris EA, Gomoll AH, Malizos KN, Hu JC, Athanasiou KA. Repair and tissue engineering techniques for articular cartilage. Nature Reviews Rheumatology. 2015;11:21–34. doi:10.1038/nrrheum.2014.157 ↩
  4. Le H, Xu W, Zhuang X, et al. Mesenchymal stem cells for cartilage regeneration. Journal of Tissue Engineering. 2020;11:2041731420943839. doi:10.1177/2041731420943839 ↩
  5. Hashimoto Y, Nishida Y, Takahashi S, et al. Transplantation of autologous bone marrow-derived MSCs with microfracture versus microfracture alone. Regenerative Therapy. 2019;11:106–113. doi:10.1016/j.reth.2019.06.002 ↩
  6. Kim SH, Ha CW, Park YB, Nam E, Lee JE, Lee HJ. Intra-articular injection of MSCs for clinical outcomes and cartilage repair in knee osteoarthritis. Archives of Orthopaedic and Trauma Surgery. 2019;139:971–980. doi:10.1007/s00402-019-03140-8 ↩
  7. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of MSCs for knee osteoarthritis: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254–1266. doi:10.1002/stem.1634 ↩
  8. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular autologous adipose-derived MSCs for knee osteoarthritis: a phase IIb randomized placebo-controlled trial. Stem Cells Translational Medicine. 2019;8(6):504–511. doi:10.1002/sctm.18-0122 ↩
  9. Park YB, Ha CW, Lee CH, Yoon YC, Park YG. Cartilage regeneration using allogeneic umbilical cord blood-derived MSCs and hyaluronate hydrogel. Stem Cells Translational Medicine. 2017;6(2):613–621. doi:10.5966/sctm.2016-0157 ↩
  10. Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular MSCs in osteoarthritis of the knee: clinical outcomes and evidence of cartilage repair. Arthroscopy. 2019;35(1):277–288.e2. doi:10.1016/j.arthro.2018.07.028 ↩
  11. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315–317. doi:10.1080/14653240600855905 ↩
  12. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived MSC transplantation for cartilage repair in 41 patients. Journal of Tissue Engineering and Regenerative Medicine. 2011;5(2):146–150. doi:10.1002/term.299 ↩
  13. Toh WS, Lai RC, Hui JHP, Lim SK. MSC exosome as a cell-free MSC therapy for cartilage regeneration. Seminars in Cell & Developmental Biology. 2017;67:56–64. doi:10.1016/j.semcdb.2016.11.008 ↩
  14. Matas J, Orrego M, Amenabar D, et al. Umbilical cord-derived MSCs for knee osteoarthritis: repeated dosing versus single dose and hyaluronic acid. Stem Cells Translational Medicine. 2019;8(3):215–224. doi:10.1002/sctm.18-0053 ↩
  15. Xiang XN, Zhu SY, He HC, Yu X, Xu Y, He CQ. Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis. Stem Cell Research & Therapy. 2022;13:14. doi:10.1186/s13287-021-02689-9 ↩